Literature DB >> 28476777

Disease Stage-Dependent Changes in Cardiac Contractile Performance and Oxygen Utilization Underlie Reduced Myocardial Efficiency in Human Inherited Hypertrophic Cardiomyopathy.

Ahmet Güçlü1, Paul Knaapen2, Hendrik J Harms2, Rahana Y Parbhudayal2, Michelle Michels2, Adriaan A Lammertsma2, Albert C van Rossum2, Tjeerd Germans2, Jolanda van der Velden2.   

Abstract

BACKGROUND: Reduced myocardial efficiency represents a target for therapy in hypertrophic cardiomyopathy although therapeutic benefit may depend on disease stage. Here, we determined disease stage-dependent changes in myocardial efficiency and effects of myectomy surgery. METHODS AND
RESULTS: Myocardial external efficiency (MEE) was determined in 27 asymptomatic mutation carriers (genotype positive/phenotype negative), 10 patients with hypertrophic obstructive cardiomyopathy (HOCM), 10 patients with aortic valve stenosis, and 14 healthy individuals using [11C]-acetate positron emission tomography and cardiovascular magnetic resonance imaging. Follow-up measurements were performed in HOCM and aortic valve stenosis patients 4 months after surgery. External work did not differ in HOCM compared with controls, whereas myocardial oxygen consumption was lower in HOCM. Because of a higher cardiac mass, total cardiac oxygen consumption was significantly higher in HOCM than in controls and genotype positive/phenotype negative. MEE was significantly lower in genotype positive/phenotype negative than in controls (28±6% versus 42±6%) and was further decreased in HOCM (22±5%). In contrast to patients with aortic valve stenosis, MEE was not improved in patients with HOCM after surgery, which was explained by opposite changes in the septum (decrease) and lateral (increase) wall.
CONCLUSIONS: Different mechanisms underlie reduced MEE at the early and advanced stage of hypertrophic cardiomyopathy. The initial increase and subsequent reduction in myocardial oxygen consumption during disease progression indicates that energy deficiency is a primary mutation-related event, whereas mechanisms secondary to disease remodeling underlie low MEE in HOCM. Our data highlight that the benefit of therapies to improve energetic status of the heart may vary depending on the disease stage and that treatment should be initiated before cardiac remodeling.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  aortic valve stenosis; cardiomyopathy, hypertrophic; energy metabolism; hypertrophy; positron-emission tomography

Mesh:

Year:  2017        PMID: 28476777     DOI: 10.1161/CIRCIMAGING.116.005604

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  19 in total

1.  Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits.

Authors:  Paul J M Wijnker; Vasco Sequeira; Diederik W D Kuster; Jolanda van der Velden
Journal:  Antioxid Redox Signal       Date:  2018-04-11       Impact factor: 8.401

2.  Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy.

Authors:  Sara Ranjbarvaziri; Kristina B Kooiker; Mathew Ellenberger; Giovanni Fajardo; Mingming Zhao; Alison Schroer Vander Roest; Rahel A Woldeyes; Tiffany T Koyano; Robyn Fong; Ning Ma; Lei Tian; Gavin M Traber; Frandics Chan; John Perrino; Sushma Reddy; Wah Chiu; Joseph C Wu; Joseph Y Woo; Kathleen M Ruppel; James A Spudich; Michael P Snyder; Kévin Contrepois; Daniel Bernstein
Journal:  Circulation       Date:  2021-10-21       Impact factor: 39.918

3.  Left Ventricular Myocardial Remodeling and Prognostic Marker Derived from Postmyectomy Cardiac MRI Feature Tracking in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Shujuan Yang; Keshan Ji; Xiuyu Chen; Fei Li; Kai Yang; Shiqin Yu; Yucong Zheng; Yanyan Song; Kankan Zhao; Minjie Lu; Shengwei Wang; Shuiyun Wang; Shihua Zhao
Journal:  Radiol Cardiothorac Imaging       Date:  2022-03-24

4.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

Review 5.  Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Jolanda van der Velden; Carlo G Tocchetti; Gilda Varricchi; Anna Bianco; Vasco Sequeira; Denise Hilfiker-Kleiner; Nazha Hamdani; Adelino F Leite-Moreira; Manuel Mayr; Ines Falcão-Pires; Thomas Thum; Dana K Dawson; Jean-Luc Balligand; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

6.  Increasing sensitivity-a common-sense approach?

Authors:  M Michels; F W Asselbergs; J van der Velden
Journal:  Neth Heart J       Date:  2019-06       Impact factor: 2.380

7.  Association between Lifelong Physical Activity and Disease Characteristics in HCM.

Authors:  Vincent L Aengevaeren; D H Frank Gommans; Hendrik-Jan Dieker; Janneke Timmermans; Freek W A Verheugt; Jeannette Bakker; Maria T E Hopman; Menko-Jan DE Boer; Marc A Brouwer; Paul D Thompson; Marcel J M Kofflard; G Etienne Cramer; Thijs M H Eijsvogels
Journal:  Med Sci Sports Exerc       Date:  2019-10       Impact factor: 5.411

Review 8.  Metabolic Alterations in Inherited Cardiomyopathies.

Authors:  Claudia Sacchetto; Vasco Sequeira; Edoardo Bertero; Jan Dudek; Christoph Maack; Martina Calore
Journal:  J Clin Med       Date:  2019-12-12       Impact factor: 4.241

9.  Increased Myocardial Oxygen Consumption Precedes Contractile Dysfunction in Hypertrophic Cardiomyopathy Caused by Pathogenic TNNT2 Gene Variants.

Authors:  Rahana Y Parbhudayal; Hendrik J Harms; Michelle Michels; Albert C van Rossum; Tjeerd Germans; Jolanda van der Velden
Journal:  J Am Heart Assoc       Date:  2020-04-15       Impact factor: 5.501

10.  Cardiac mechanical efficiency is preserved in primary cardiac hypertrophy despite impaired mechanical function.

Authors:  June-Chiew Han; Kenneth Tran; David J Crossman; Claire L Curl; Parisa Koutsifeli; Joshua P H Neale; Xun Li; Stephen B Harrap; Andrew J Taberner; Lea M D Delbridge; Denis S Loiselle; Kimberley M Mellor
Journal:  J Gen Physiol       Date:  2021-06-28       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.